ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) is annually awarding the Rudolf Buchheim Award. This year the Rudolf Buchheim Award was awarded to Julian Peter Müller for outstanding work of a young researcher in the field of clinical pharmacology. He investigated the performance and applicability of the novel CYP2D6 biomarker solanidine. CYP2D6 is a genotypic and phenotypic highly variable drug-metabolizing enzyme involved in the metabolism of about 20% of commonly used drugs. Variability in CYP2D6 activity may lead to pronounced interindividual deviations in the pharmacokinetics of its drug substrates, potentially leading to adverse events or therapy failure. CYP2D6 genotyping allows to predict metabolizer phenotypes, e.g., poor, intermediate, normal or ultrarapid, but cannot take into account additional variation due to co-medication or other factors. In the awarded work he could demonstrate that a single plasma sample is sufficient for accurate CYP2D6 phenotyping, and that by using solanidine, CYP2D6 phenoconversion, a genotype-phenotype mismatch, due to polypharmacy can be elucidated. The use of the CYP2D6 biomarker solanidine allows to study non-genetic variation of CYP2D6 activity and opens up new possibilities in personalized medicine. Application of solanidine phenotyping may help to understand factors of CYP2D6 phenoconversion and may be applied with patients to optimize therapy decisions and to improve outcomes and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.